Want to see GB:SYNC full AI Analyst Report?
SYNC Stock Chart & Stats
107.00 p
-0.80 p(-0.74%)
At close: 4:00 PM EDT
107.00 p
-0.80 p(-0.74%)
Day’s Range― - ―
52-Week Range86.80 p - 109.80 p
Previous CloseN/A
Volume190.55K
Average Volume (3M)483.92K
Market Cap
£655.63M
Enterprise Value589.73M
Total Cash (Recent Filing)£1.92M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding608,193,050
10 Day Avg. Volume510,558
30 Day Avg. Volume483,919
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)0.52
Price to Sales (P/S)9.39
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£189.00Price Target Upside76.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)<0.01
Revenue Forecast (FY)£49.14M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported total debt materially reduces financial risk and preserves strategic optionality. For an investment company that funds long clinical cycles, a debt-free structure enables Syncona to support portfolio companies through follow-on funding without immediate refinancing pressure, improving resilience across downturns and preserving ability to back high-conviction assets over multi-year horizons.
Large Equity Capital BaseA substantial equity base provides durable firepower to incubate and scale biotech companies and to sustain long development timelines. Large equity cushions NAV volatility, lowers immediate dilution risk for follow-ons, and allows Syncona to maintain meaningful ownership stakes that preserve upside capture when portfolio companies reach value inflection points or exit.
Company-builder, Long-term Capital ModelSyncona’s active company-building model aligns capital and operational support with portfolio progress, not just passive exposure. Long-term capital provision and hands-on governance increase the chance of clinical and commercial milestones, helping de-risk programs and potentially accelerate realizations versus passive investors, a durable competitive advantage in life sciences investing.
Bears Say
Volatile ProfitabilityShifting from profit to multi-year losses signals inconsistent return generation from invested capital. For an investment company, unreliable profitability weakens the track record used to attract co-investors and can compress reinvestment capacity. Persistent losses also reduce visible evidence of repeatable value creation across portfolio cycles.
Free Cash Flow Decline To ZeroA fall to zero free cash flow limits the firm's internal ability to fund follow-on investments or absorb setbacks without raising capital or selling assets. For a builder of late-stage biotech companies, constrained FCF increases reliance on external financing, which can dilute holdings, slow development, or force suboptimal exits during stressed market conditions.
Significant Revenue ContractionA ~41% revenue decline reflects weakening operating receipts or realization activity and reduces near-term ability to convert NAV into distributable cash. Structural revenue contraction undermines momentum in demonstrating scalable returns and raises questions about timing and predictability of future monetization events that drive investor returns in a life-sciences investment vehicle.
Syncona Shs GBP News
SYNC FAQ
What was Syncona Shs GBP ’s price range in the past 12 months?
Syncona Shs GBP lowest share price was 86.80 p and its highest was 109.80 p in the past 12 months.
What is Syncona Shs GBP ’s market cap?
Syncona Shs GBP ’s market cap is £655.63M.
When is Syncona Shs GBP ’s upcoming earnings report date?
Syncona Shs GBP ’s upcoming earnings report date is Nov 12, 2026 which is in 91 days.
How were Syncona Shs GBP ’s earnings last quarter?
Syncona Shs GBP released its earnings results on Jun 18, 2026. The company reported 0.027 p earnings per share for the quarter, beating the consensus estimate of N/A by 0.027 p.
Is Syncona Shs GBP overvalued?
According to Wall Street analysts Syncona Shs GBP ’s price is currently Undervalued.
Does Syncona Shs GBP pay dividends?
Syncona Shs GBP pays a Annually dividend of 2.3 p which represents an annual dividend yield of N/A. See more information on Syncona Shs GBP dividends here
What is Syncona Shs GBP ’s EPS estimate?
Syncona Shs GBP ’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Syncona Shs GBP have?
Syncona Shs GBP has 608,193,050 shares outstanding.
What happened to Syncona Shs GBP ’s price movement after its last earnings report?
Syncona Shs GBP reported an EPS of 0.027 p in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.99%.
Which hedge fund is a major shareholder of Syncona Shs GBP ?
Currently, no hedge funds are holding shares in GB:SYNC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Syncona Shs GBP Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
£189.00 (76.64% Upside)
£189.00 (76.64% Upside)
Insider Transactions
Bought Shares
Worth £16.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-2.90%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.14%
Trailing 12-Months
Company Description
Syncona Shs GBP
Syncona Ltd. is a closed-end investment fund, which engages in delivering returns from investments in long and alternative investment funds across multiple asset classes and targets. Its portfolio includes commercial companies, late-stage clinical companies, clinical companies, and pre-clinical companies. The company was founded on August 14, 2012 and is headquartered in St. Peter Port, the United Kingdom.
SYNC Stock 12 Month Forecast
Average Price Target
189.00 p
▲(76.64% Upside)
Technical Analysis
Ashmore Group PLC
―
Molten Ventures
―
IP Group plc
―
Mercia Asset Management
―
Caledonia Investments
―